The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) posted a devastating global health crisis for almost a year already. Very little is known about this virus that scientists, physicians and the medical community struggled to find treatments of this novel virus. The vaccine that can potentially combat this virus is still an unknown reality hence, the repurposing of existing medical treatments such as chlorpheniramine maleate (CPM) could be a possible treatment and is being widely utilized. CPM is a safe and effective antihistamine with potent antiviral activity against various strains of influenza A/B, thus highlighting its great antiviral potential. We tested the virucidal potential of chlorpheniramine maleate (CPM) in a nasal spray composition currently in development as an anti-allergy medication.
The coronavirus disease 2019 (COVID-19) has a droplet mode transmission with a notably high viral load in the upper respiratory tract, especially the nose. Several studies had already postulated that the nose is possibly the primary route of entry of SARS-CoV-2 owing to the high expression of Angiotensin 2 converting enzyme receptors. We hypothesize that utilizing (CPM) nasal spray as an adjunct treatment to COVID-19 positive patients and reduce their clinical course and hasten their time to negativization via RT-PCR via nasopharyngeal swab. We present a series of four symptomatic patients with mild-moderate risks. CPM nasal spray was added to their current supportive treatment. All four patients showed rapid improvement of their clinical symptoms with a shorter than average time to negativization on repeat nasopharyngeal swab via RT-PCR. No safety issues were encountered during the course of treatment. Given its years of excellent safety profile with remarkable clinical results as shown in this case series, we conclude that CPM nasal spray may be a potential adjunct treatment option in patients with mild to moderate COVID-19 symptoms.